Neochem Bio Solutions Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹182 Cr
- P/E
- 12.03
- ROE
- 25.35%
- PEG
- 0.10
- Price to sales
- 1.36
- Debt to equity
- 0.38
- 52W high / low
- ₹116 / ₹63.2
- EBITDA margin
- 17.42%
- Net profit margin
- 11.29%
- Promoter holding
- 66.88%
- Sales (last year)
- ₹134 Cr
Incorporated in 2006, Neochem Bio Solutions Ltd. is engaged in the business of manufacturing of specialty performance chemicals.[1]
Guidance scorecard · Q2 FY27 call
What Neochem Bio's management guided
and where it ranks in Chemicals & Petrochemicals
Chemicals & Petrochemicals
RevenueQ2 FY27 call
40%+- Neochem Bio Solutions aims for a revenue growth of more than 40% CAGR this year and over the next 5-6 years.
- Volumes grew 20% year-on-year in H1 FY2027; capacity utilization is targeted to reach approximately 65% by end of FY2027 and 75% by next year.
- The company expects volume growth of 20%-25% going forward, supported by better customer acquisition and product mix.
- Textile business volume will grow in absolute numbers, though its percentage contribution to revenue may decrease as focus shifts to higher-margin specialty products.
2 more points from Neochem Bio's call on revenue
Create a free account to keep reading this call
MarginsQ2 FY27 call
FlatSee what Neochem Bio said on margins — free account, 30 seconds.
CapexQ2 FY27 call
Planned- No major capex requirements are expected over the medium term.
- The company plans to start dividend payments soon after achieving early capex goals.
- Continuous small capex is ongoing to improve operational and warehousing efficiencies.
- Capacity can be expanded internally by replacing smaller reactors with larger ones quickly.
- Adjacent industrial land is available for further capex, but currently undergoing government reorganization.
- The land available could support growth for the next 5 to 7 years.
- Short- and medium-term capex will happen within the existing facility.
2 more points from Neochem Bio's call on capex
Create a free account to keep reading this call
FundraisingQ2 FY27 call
See what Neochem Bio said on fundraising — free account, 30 seconds.
Order bookQ2 FY27 call
RisingAsk what Neochem Bio said on the order book →
Full Q2 FY27 analysisRanges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Chemicals & Petrochemicals companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 0–2% | ₹234 Cr | 3.0 | |
| 2 | 40%+ | Flat | ₹3,888 Cr | 48.5 | |
| 3 | 40%+ | Flat | ₹3,514 Cr | 4.3 | |
| 4 | Neochem BioThis stock | 40%+ | Flat | ₹180 Cr | 11.9 |
| 5 | 40%+ | Flat | ₹138 Cr | 15.1 | |
| 6 | 20–40% | Up 2%+ | ₹1.70L Cr | 85.4 |
Sign up free to see every company in the sector ranking and track Neochem Bio.
Pro shows every company guiding 40%+ revenue growth →Full Chemicals & Petrochemicals rankingFinancials of Neochem Bio
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Neochem Bio
Shareholding breakup across reporting periods.
| Dec 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|
| Promoters + | 66.70% | 66.72% | 66.88% |
| FIIs + | 1.99% | 0.18% | 0.18% |
| DIIs + | 13.19% | 15.82% | 12.46% |
| Public + | 18.12% | 17.28% | 20.47% |
| No. of Shareholders | 861 | 406 | 525 |
Financials of Neochem Bio
Quarterly Results
Quarter-by-quarter operating performance
Financials of Neochem Bio
Profit & Loss
Annual income statement trend
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| Sales + | 49 | 48 | 61 | 84 | 111 | 134 |
| Expenses + | 45 | 44 | 55 | 71 | 91 | 110 |
| Operating Profit | 4 | 4 | 6 | 13 | 20 | 23 |
| OPM % | 7% | 9% | 10% | 15% | 18% | 17% |
| Other Income + | 0 | 1 | 1 | 2 | 2 | 1 |
| Interest | 1 | 2 | 3 | 4 | 4 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 2 | 3 | 10 | 17 | 20 |
| Tax % | 25% | 28% | 31% | 25% | 30% | |
| Net Profit + | 1 | 1 | 2 | 7 | 12 | 15 |
| EPS in Rs | 1.87 | 1.20 | 1.65 | 6.36 | 7.03 | 8.60 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Financials of Neochem Bio
Balance Sheet
Capital structure and asset base
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 3 | 5 | 7 | 7 | 17 | 17 |
| Reserves | 1 | 3 | 6 | 13 | 62 | 70 |
| Borrowings + | 23 | 26 | 33 | 36 | 18 | 33 |
| Other Liabilities + | 19 | 16 | 18 | 24 | 20 | 29 |
| Total Liabilities | 46 | 51 | 63 | 79 | 117 | 149 |
| Fixed Assets + | 12 | 15 | 19 | 19 | 20 | 31 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 3 |
| Investments | 0 | 0 | 0 | 0 | 6 | 5 |
| Other Assets + | 34 | 36 | 45 | 60 | 91 | 110 |
| Total Assets | 46 | 51 | 63 | 79 | 117 | 149 |
Financials of Neochem Bio
Cash Flows
Operating, investing and financing cash movement
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from Operating Activity + | -1 | -1 | -1 | 2 | -17 |
| Cash from Investing Activity + | -3 | -3 | 12 | -1 | -9 |
| Cash from Financing Activity + | 4 | 4 | -11 | -1 | 26 |
| Net Cash Flow | 0 | -0 | 0 | -0 | 0 |
| Free Cash Flow | -4 | -4 | 11 | 1 | -19 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -36% | -23% | -10% | 23% | -70% |
Financials of Neochem Bio
Ratios
Working capital efficiency and return ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 102 | 107 | 100 | 110 | 161 |
| Inventory Days | 141 | 173 | 172 | 157 | 143 |
| Days Payable | 186 | 155 | 142 | 111 | 56 |
| Cash Conversion Cycle | 58 | 125 | 131 | 156 | 247 |
| Working Capital Days | 17 | 19 | 30 | 39 | 164 |
| ROCE % | 12% | 14% | 26% | 28% |
Guidance history
How Neochem Bio's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q2 FY27 call → | 40%+ | Flat | Planned | — | Rising |
| Q4 FY26 call → | 20–40% | Flat | None planned | — | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Continue your research
What Neochem Bio's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Camlin Fine (Q2 FY27)
Q2 FY27 revenue: Rs 4,915 mn, up 9.15% YoY from Rs 4,503 mn in Q2 FY26 (Page 6, 9) . Key investor presentation takeaways from Camlin Fine Sciences Ltd's Q2 FY27
- Gujarat Fluoroch (Q2 FY27)
Consolidated Q2FY27 revenue: ₹1,760 crore, up 45% YoY (Q2FY26: ₹1,210 crore). Key investor presentation takeaways from Gujarat Fluorochemicals Ltd's Q2 FY27 inv
- Bodal Chemicals (Q2 FY27)
8,840 mn, up 77% YoY (from Rs. Key investor presentation takeaways from Bodal Chemicals Ltd's Q2 FY27 investor presentation — and how it ranks against sector pe
- Solar Industries (Q2 FY27)
3,519 crore, up 69% YoY from Rs. Key investor presentation takeaways from Solar Industries India Ltd's Q2 FY27 investor presentation — and how it ranks against